ArticleAlzheimer's & dementia (New York, N. Y.)2019
Economic impacts of introducing diagnostics for mild cognitive impairment Alzheimer's disease patients.
Article in Alzheimer's & dementia (New York, N. Y.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Are diagnostic technologies for alzheimer's disease and dementia cost-effective? A systematic review of economic evaluations.Alzheimer's research & therapy · 2026Pooled it
- Innovations in dementia screening: a systematic review and meta-analysis of virtual reality assessments.Frontiers in psychology · 2025Pooled it
- Cost analyses of plasma p-tau217 versus p-tau217/Aβ42 ratio using two-step approach in the Japanese health care system.The journal of prevention of Alzheimer's disease · 2026Article
- Functional imaging constrained diffusion for brain PET synthesis from structural MRI.Medical image analysis · 2026Article
- AI-Based Dementia Prediction From Low-Dose Brain CT in Mild Cognitive Impairments.Dementia and neurocognitive disorders · 2026Article
- Integration of AI diagnostic tools into clinical practice for Alzheimer's disease: barriers and solutions.Annals of medicine and surgery (2012) · 2026Review
- Artificial Intelligence-Enhanced Multi-Algorithm R Shiny Application for Predictive Modeling and Analytics: Case Study of Alzheimer Disease Diagnostics.JMIR aging · 2025Article
- Use of Amyloid Positron-Emission Tomography to Diagnose Alzheimer's Disease in Clinical Practice in South Korea: Expert Recommendations.Journal of clinical neurology (Seoul, Korea) · 2025Review
- Machine learning models for dementia screening to classify brain amyloid positivity on positron emission tomography using blood markers and demographic characteristics: a retrospective observational study.Alzheimer's research & therapy · 2025Observational
- Alzheimer's diagnosis beyond cerebrospinal fluid: Probe-Free Detection of Tau Proteins using MXene based redox systems and molecularly imprinted polymers.Biosensors & bioelectronics: X · 2024Article
- Use of a Blood Biomarker Test Improves Economic Utility in the Evaluation of Older Patients Presenting with Cognitive Impairment.Population health management · 2024Article
- Machine learning prediction of future amyloid beta positivity in amyloid-negative individuals.Alzheimer's research & therapy · 2024Article
- Estimated Investment Need to Increase England's Capacity to Diagnose Eligibility for an Alzheimer's Treatment to G7 Average Capacity Levels.The journal of prevention of Alzheimer's disease · 2024Article
- The Role of Non-coding RNAs in Alzheimer's Disease: Pathogenesis, Novel Biomarkers, and Potential Therapeutic Targets.CNS & neurological disorders drug targets · 2024Review
- Profiling of plasma biomarkers in the context of memory assessment in a tertiary memory clinic.Translational psychiatry · 2023Article
- Alzheimer's disease-associated complement gene variants influence plasma complement protein levels.Journal of neuroinflammation · 2023Article
- Remote data collection speech analysis in people at risk for Alzheimer's disease dementia: usability and acceptability results.Frontiers in dementia · 2023Article
- Current Diagnostic Pathways for Alzheimer's Disease: A Cross-Sectional Real-World Study Across Six Countries.Journal of Alzheimer's disease reports · 2023Article
- Advances in the development of new biomarkers for Alzheimer's disease.Translational neurodegeneration · 2022Review
- Syndecan-3 as a Novel Biomarker in Alzheimer's Disease.International journal of molecular sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDisease-modifying treatments for Alzheimer's disease (AD) are likely to be offered only to patients with molecular evidence for Alzheimer pathology and expanded to patients with prodromal AD. We calculated the potential future costs of expanding the number of positron emission tomography (PET) and cerebrospinal fluid (CSF) tests in the United Kingdom.
methodsWe conducted a focused literature review and consulted experts to obtain information on the current use of PET and CSF to diagnose prodromal AD, staffing and equipment requirements for these tests, and associated costs.
resultsWe estimate annual costs of 100,000 extra amyloid PET scans and 100,000 extra CSF tests at £113 million and £48 million, respectively; these costs are likely to be higher in the first year. DISCUSSION: The budgetary impacts are not insignificant but are small in comparison to the likely market price of any disease-modifying treatments or to the probable costs of missed or inaccurate diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.